Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis (Q39704084)

14 September 2017

Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis (English)

1 reference

14 September 2017

0 references

Bing Wang

1

1 reference

14 September 2017

Yvonne Y Lau

2

1 reference

14 September 2017

Meina Liang

3

1 reference

14 September 2017

Inna Vainshtein

4

1 reference

14 September 2017

Mikhail Zusmanovich

5

1 reference

14 September 2017

Hong Lu

6

1 reference

14 September 2017

Fabio Magrini

7

1 reference

14 September 2017

Matthew Sleeman

8

1 reference

14 September 2017

Lorin Roskos

9

1 reference

14 September 2017

23 September 2011

1 reference

The Journal of Clinical Pharmacology

14 September 2017

1 reference

14 September 2017

52

1 reference

14 September 2017

8

1 reference

14 September 2017

1150-1161

1 reference

GM-CSF in inflammation and autoimmunity.

14 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Colony-stimulating factors in inflammation and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Stability and performance of a population pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Approximations of the target-mediated drug disposition model and identifiability of model parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

The determination of plasma volume in man with radioactive chromic chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Granulocyte-macrophage colony-stimulating factor (GM-CSF) and inflammatory stimuli up-regulate secretion of the soluble GM-CSF receptor in human monocytes: evidence for ectodomain shedding of the cell surface GM-CSF receptor alpha subunit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Specific human granulocyte-macrophage colony-stimulating factor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412964

21 January 2018

Identifiers

DOI

10.1177/0091270011412964

1 reference

14 September 2017

1 reference